Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesIloperidone: In Schizophrenia
CNS Drugs, 09/16/09
Scott LJ – Iloperidone is an atypical antipsychotic that is approved for the treatment of adult patients with schizophrenia. Iloperidone was generally well tolerated and was associated with few extrapyramidal symptoms or changes in metabolic parameters in short– and longer–term clinical trials in adult patients with schizophrenia.
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Today in Schizophrenia/Psychosis...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
Schizophrenia Research, 11/18/09
Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate
Asian Journal of Psychiatry, 11/09/09
Sponsor
Article Search
Sponsor